anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Examples provide a workforce manager that analyzes historical pharmacy transaction data to generate a set of forecasted future prescriptions for a selected pharmacy. The forecasted future prescriptions are divided into predicted new prescriptions and predicted refill prescriptions. The predicted refill prescriptions are classified into a set of high confidence refills and a set of low confidence refills. The labor demand associated with the set of high confidence refills are redistributed within a range of pickup dates associated with each high confidence refill prescription to smooth labor demand minimizing variation within a selected time-period. A number of personnel are identified for each day in the selected time-period based on the smoothed labor demand. A schedule is published assigning at least a portion of the forecasted future prescriptions and the number of personnel to each day in the selected time-period is output.
Background: Integrative medicine (IM) is the healing-oriented practice of medicine that emphasizes the relationship between practitioner and patient. It considers the whole person, their environment, lifestyle, and social and cultural factors. It is evidence based and makes use of all appropriate therapies, conventional and complimentary. Objective: To evaluate the impact of IM services on health outcomes and care costs of chronic pain management patients compared with standard care. Methods: This article uses University of New Mexico hospital billing data from 10/2016 to 09/2019 to identify patients with nervous system or musculoskeletal pain. A total of 1,304 patients were matched using propensity scores into IM services (treatment: 652) and standard care (control: 652) cohorts for difference-in-differences analysis. The patients were matched based on age, sex, race, zip code, insurance type, ICD-10s, prescriptions, health care events, and medical claim costs. Results: Patients who used IM services had better health outcomes and lower costs at 3-month, 6-month, and 12-month follow-up. At the 12-month follow-up, the IM group showed a 19% decrease in utilization of inpatient care, a 37% decrease in Emergency Department utilization, and an 11.3% reduction in claim costs compared with the control group. Conclusion: Patients who utilize IM services as part of chronic pain management have overall lower health care costs and better health outcomes. Unfortunately, in the health system studied, less than 3% of patients utilize these services. Promotion of and education about IM services should be aimed at both patients and their providers.
BACKGROUND: Genital nerve stimulation (GNS) is a promising, but under-researched, alternative treatment for neurogenic detrusor overactivity (NDO) in those with spinal cord injury (SCI).
OBJECTIVES: To investigate the urodynamic, quality-of-life (QOL) and carry-over effects of GNS when applied at home for 2 weeks by participants with incomplete SCI and NDO during activities of daily living.
METHODS: Seven men and 1 woman participated in this 1-month protocol study. Urodynamic and QOL data were gathered during week 1 (baseline measurements), followed by 2 weeks of daily GNS at home using a portable device. GNS was applied either on-demand or thrice daily, depending on the individual's sensation. At week 4, post-stimulation tests were repeated to record any carry-over effect from the GNS. Participants maintained voiding diaries throughout the study. Assessments were carried out at the end of each protocol period in a randomized order. Clinical procedures were conducted at Taipei Medical University Hospital (Taipei, Taiwan).
RESULTS: Everyone completed the study but only 7 of the 8 participants completed their voiding diary. Two weeks after GNS, average cystometric bladder capacity was increased by 30 % compared to baseline (P< 0.05). A 1-week carry-over effect was demonstrated as this capacity remained, on average, 35 % greater than baseline in week 4 after GNS was stopped (P< 0.05). Incontinence frequency significantly decreased by the end of week 3 (P< 0.05) but no significant improvements were recorded for either detrusor pressure or bladder compliance.
CONCLUSIONS: Chronic at-home GNS improved cystometric bladder capacity and reduced urinary incontinence for individuals with incomplete SCI and NDO. A carry-over effect of 1 week was observed following GNS treatment. The use of portable GNS treatment that can be applied by the individual at home merits further investigation as alternative treatment for NDO in those with SCI.
A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to tablets for oral use and provides the sustained-release an active substance. Agent has the moisture-nonsensitive pharmaceutically acceptable tramadol salt as an active substance taken at amount 10-85 wt.-%. Agent has also usual for tabletted form accessory additions and as a pharmaceutically acceptable matrix forming agent - at least one ether and/or ester of cellulose at amount 10-40 wt. -% at viscosity 3 000-150 000 MP ads at 20 C in 2 wt.-% an aqueous solution. New drug releases tramadol salt independently on pH value of an environment, type and amount of filling agent. At given mass and form of tablet the pattern of release of tramadol salt does not depend on the content of biologically active substance and amount of matrix forming agent. EFFECT: improved quality of the drug. 5 cl, 3 dwg, 8 ex
Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
The invention provides a polypeptide comprising a sequence as set forth in any one of SEQ ID NOs 1 to 8. Also provided is a composition comprising a polypeptide having the sequence shown in SEQ ID No. 7, cefotaxime and sulbactam. The polypeptide with the sequence of SEQ ID NO. 7 has strong activity for inhibiting escherichia coli or listeria monocytogenes. After the polypeptide is combined with cefotaxime sulbactam, the activity of the polypeptide for inhibiting the escherichia coli producing beta-lactamase is strong. The polypeptides and compositions are therefore of great clinical value.
Imaginal Exposure (IE) involves repeatedly "reliving" a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session.
PURPOSE:To provide an infusion solution preparation effective for the physical strength maintenance and immune function improvement of patients fallen in an intravital protein catabolism-accelerating state by containing 3- hydroxybutyric acid having (R) type steric configuration or a salt thereof. CONSTITUTION:An infusion solution preparation for supplying energy to patients fallen in a intravital protein catabolism-accelerating state, e.g. a patient having stress in his body, a patient lowered in the function of his liver or a patient unable to orally ingest foods and for inhibiting the intravital protein metabolism of the patients contains 3-hydroxybutyric acid having (R) type steric configuration or a salt thereof (e.g. Na salt, L-lysine salt or L-histidine salt). The infusion solution preparation is preferably adjusted e.g. to an inorganic electrolyte- containing extracellular supplementary solution having a 3-hydroxybutyric acid concentration of 0.30-0.85wt.%, a pH of 4.5-8.0 and an osmotic pressure ratio of 0.7-1.7 or to a maintenance infusion solution having a 3-hydroxybutyric acid concentration of 0.18-2.4wt.%, a pH of 4.0-8.0 and an osmotic pressure ratio of 1.0-3.0 and subsequently directly administered into a vein.
Endo-antigenic extracts of Staphylococcus aureus are prepd. by following process (a) S. aureus is cultured in a medium contg. peptone, NaCl, yeast extract and glucose (b) the culture medium is centrifuged to give the bacterial deposit (c) this deposit is resuspended in a glycine soln contg. polyvinyl pyrrolidone and kept at 37 degrees C until lysis is complete (d) the lysate is centrifuged and the supernatant layer recovered (e) this layer is treated with sodium mercurothiolate to detoxify the endo-antigens. Used as reagents for serological research. They detect the presence of flocculating and precipitating antistaphylococcal antibodies in human or animal serum.
All subjects will participate in a 2x/week for 6 weeks exercise program using Frei FACTUM® novus II line exercise equipment, which uses hydraulic resistance. Each session will take 30-45 minutes to complete. The equipment uses concentric movements only but works both agonist and antagonist muscles with each piece of equipment (IE: push and pull). Participants results will be compared pre and post intervention.
BACKGROUND: Nosocomial infections are a global problem in hospitals all around the world. It is considered a major health problem, especially in developing countries. The increase in the patient's stay in hospitals has increased the mortality rate, and consequently, the costs drastically increase. The main purpose of using disinfectants in the hospital environment is to reduce the risk of nosocomial infections. Ethylene diamine tetra acetic acid (EDTA) causes lysis and increases susceptibility to antimicrobial agents in the planktonic form of bacteria. This substance affects the permeability of the outer membrane of bacteria. It also prevents the formation of biofilms by bacteria.
MATERIALS AND METHODS: In the current study, 120 isolates of Acinetobacter baumannii (A. baumannii) were confirmed by phenotypic and genotypic methods. Antibiogram was performed and then the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of isolates against 5% sodium hypochlorite, ethanol %70, sayasept-HP 2%, chlorhexidine 2%, dettol 4/8% were evaluated. In addition, the disinfectant effect was re-evaluated with the mixture of EDTA solution. All isolates were examined for biofilm presence by crystal violet staining method in triplicates and repeated three times for each strain. Also for all isolates detection of efflux pump genes (Qac-E, qacE-Δ1, SUG-E) by PCR technique was done.
RESULTS: Antibiogram results of A. baumannii showed that 6.7% were Multi-drug-resistant (MDR), and 89.2% were Extensively drug-resistant (XDR) isolates. The highest effect of disinfectants was related to 5% sodium hypochlorite, and the least effect was 70% ethanol. EDTA increases the efficacy of selected disinfectants significantly. The highest prevalence of the efflux pump genes was related to SUG-E (95%) and Qac-E (91.7%), and, the qacE-Δ1 gene with 12.5%. The biofilm production rate was 91.3% among all isolates.
CONCLUSION: The best and safest way to disinfect hospital floors and surfaces is to choose the right disinfectants, and learn how to use them properly. In this study, a mixture of disinfectants and EDTA had a significant effect on bactericidal activity. it was found that improper use of disinfectants, especially the use of sub-inhibitory dilutions, increases the resistance of bacteria to disinfectants.
Providing interventions that facilitate improvement of dietary intake and other health behaviors can improve nutrition-related outcomes in adults with overweight or obesity. Medical nutrition therapy (MNT) behavioral interventions require expertise from registered dietitian nutritionists or international equivalents (dietitians), which no other health care provider can provide for adults with obesity. Current evidence supports the role of MNT behavioral interventions for adults with overweight or obesity as an effective treatment option, when appropriate for and desired by the client. This Academy of Nutrition and Dietetics Position Paper describes potential benefits and concerns regarding dietitian-provided MNT behavioral interventions for adults with overweight and obesity and informs dietitians about implications for practice. This Position Paper is supported by a systematic review examining effectiveness of MNT interventions provided by dietitians and by an evidence-based practice guideline. It is the position of the Academy of Nutrition and Dietetics that MNT behavioral interventions for adults (aged 18 years and older) with overweight or obesity should be a treatment option, when appropriate and desired by the client, to improve cardiometabolic, quality of life, and anthropometric outcomes. Dietitians providing MNT recognize the complex contributors to overweight and obesity, and thus individualize interventions, based on a shared decision-making process, and deliver interventions in an inclusive, compassionate, and client-centered manner. Interventions should include collaboration with an interprofessional team when needed. Dietitians strive to increase health equity and reduce health disparities by advocating and providing opportunities for increased access to effective nutrition care services. This position remains in effect until December 31, 2031.
Participants randomized to the T2CR intervention arm will receive a transitional care program designed to supplement usual care following an acute heart event. Study personnel will follow T2CR Intervention participants for the course of the 12-month study period to assess endpoints in comparison to the Usual Care arm.
Sleep disorders affect many people worldwide and can accompany neurodegenerative and psychiatric diseases. Sleep may be altered before the clinical manifestations of some of these diseases appear. Moreover, some sleep disorders affect the physiological organization and function of the brain by influencing gene expression, accelerating the accumulation of abnormal proteins, interfering with the clearance of abnormal proteins, or altering the levels of related hormones and neurotransmitters, which can cause or may be associated with the development of neurodegenerative and psychiatric diseases. However, the detailed mechanisms of these effects are unclear. This review mainly focuses on the relationship between and mechanisms of action of sleep in Alzheimer's disease, depression, and anxiety, as well as the relationships between sleep and Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. This summary of current research hotspots may provide researchers with better clues and ideas to develop treatment solutions for neurodegenerative and psychiatric diseases associated with sleep disorders.
Thirty-four patients with ASA classification I-II, who required oroendotracheal tube intubation, were studied in this prospective, double-blinded, randomized, clinical trial. Anesthesia was induced using fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg. Patients were randomly assigned to one of the two groups to receive either rocuronium 0.6 mg/kg or saline intravenously. The Mcgrath® VL intubation was initiated after 90s, when the patients were fully relaxed. The primary outcome was to compare tracheal intubating conditions between two groups. The secondary outcomes were the success rate in the first attempt intubation, time to intubation, the required propofol dose for intubation and anesthetic complications. Statistical analyses were performed using the R program version 2.14.2. The level of statistical significance was set at p \< 0.05.
A 6-month clinical trial of malignant carcinoid syndrome was performed in 93 patients who had previously been shown to be responsive to Sandostatin Injection. Sixty-seven (67) patients were randomized at baseline to receive double-blind doses of 10 mg, 20 mg, or 30 mg SANDOSTATIN LAR DEPOT every 28 days and 26 patients continued, unblinded, on their previous Sandostatin Injection regimen (100 to 300 mcg three times daily).

In any given month after steady-state levels of octreotide were reached, approximately 35% to 40% of the patients who received SANDOSTATIN LAR DEPOT required supplemental subcutaneous Sandostatin Injection therapy usually for a few days, to control exacerbation of carcinoid symptoms. In any given month, the percentage of patients randomized to subcutaneous Sandostatin Injection, who required supplemental treatment with an increased dose of Sandostatin Injection, was similar to the percentage of patients randomized to SANDOSTATIN LAR DEPOT. Over the 6-month treatment period, approximately 50% to 70% of patients who completed the trial on SANDOSTATIN LAR DEPOT required subcutaneous Sandostatin Injection supplemental therapy to control exacerbation of carcinoid symptoms although steady-state serum SANDOSTATIN LAR DEPOT levels had been reached.

Table 7 presents the average number of daily stools and flushing episodes in malignant carcinoid patients.

Overall, mean daily stool frequency was as well controlled on SANDOSTATIN LAR DEPOT as on Sandostatin Injection (approximately 2 to 2.5 stools/day).

Mean daily flushing episodes were similar at all doses of SANDOSTATIN LAR DEPOT and on Sandostatin Injection (approximately 0.5 to 1 episode/day).

In a subset of patients with variable severity of disease, median 24 hour urinary 5-HIAA (5-hydroxyindole acetic acid) levels were reduced by 38% to 50% in the groups randomized to SANDOSTATIN LAR DEPOT.

The reductions are within the range reported in the published literature for patients treated with octreotide (about 10% to 50%).

Seventy-eight (78) patients with malignant carcinoid syndrome who had participated in this 6-month trial subsequently participated in a 12-month extension study in which they received 12 injections of SANDOSTATIN LAR DEPOT at 4-week intervals. For those who remained in the extension trial, diarrhea and flushing were as well controlled as during the 6-month trial. Because malignant carcinoid disease is progressive, as expected, a number of deaths (8 patients: 10%) occurred due to disease progression or complications from the underlying disease. An additional 22% of patients prematurely discontinued SANDOSTATIN LAR DEPOT due to disease progression or worsening of carcinoid symptoms.
Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
Substantial data exists to demonstrate that improving metabolic control in persons with Type 1 diabetes mellitus (T1DM) can delay the onset of diabetes complications and reverse some existing complications as well. Unfortunately, those adolescents with T1DM who are at highest risk for diabetes complications are often the most resistant to hospital based care and traditional education/ supportive interventions. They are also faced with multiple barriers to improved metabolic control, which may include lack of knowledge about diabetes, family disorganization and disengagement, high levels of stress and an unhealthy lifestyle. Multisystemic Therapy (MST), a flexible and home-based therapeutic intervention originally designed for use with mental health populations, seems to be a promising approach to providing diabetic adolescents with the ability to engage in consistent and attentive illness management.

The study recruited a sample of 127 adolescents in poor metabolic control and randomly assigned them to either the treatment intervention, MST plus standard medical care, or standard medical care alone. Families randomized to MST received intensive, home-based family therapy for approximately six months. Families completed data collection at baseline and then again at 7, 12 18 and 24 months after study entry.
PURPOSE: A pharmaceutical composition and a food composition containing Santalum album extract of a fraction thereof for preventing neurodegenerative diseases are provided to effectively suppress acetylcholine esterase activity and nerve inflammation. CONSTITUTION: A pharmaceutical composition for preventing or treating neurodegenerative diseases contains Santalum album extract or a fraction thereof as an active ingredient. The extract is an ethanol crude extract prepared using water, low alcohol of C1-C4, or a mixture thereof. The fraction is an ethyl acetate soluble fraction, butanol soluble fraction, or water soluble fraction of the crude extract. A method for preventing or treating neurodegenerative diseases comprises a step of administering the composition to an individual with neurodegenerative diseases or risk of developing the diseases. [Reference numerals] (AA) Ethanol crude extract; (BB) Butanol soluble fraction extract; (CC, FF) Acetylcholine esterase suppression ability(%); (DD) Ethyl acetate soluble fraction extract; (EE) Water soluble fraction extract
Postoperative ileus (POI) is temporary slowing down or stopping of bowel function and a slowing down of movement of contents of the intestines. This functional impairment persists for a variable duration following surgery, usually resolving within 1 day in the small intestine, 1 to 3 days in the stomach and 3 to 5 days in the colon. When POI persists for more than 5 days, it is generally considered severe, sometimes referred to as complicated or prolonged POI, and increases the risk for related morbidity. This is a randomized, controlled, double-blind study designed to evaluate the tolerability and efficacy of DAM solution for the treatment of POI in patients following abdominal operation. It will be conducted at multiple centers in China. A total of 480 patients will be enrolled in the study. Patient participation in the study will last for up to postoperative day 7 \[POD 7\] , with follow-up safety assessments to occur 7 days after the operation.The treatment outcome measures include: 1) GI2(Time to achieve recovery of both upper and lower GI function as measured by a composite endpoint of time to the first bowel movement and time to tolerate first solid food). 2) Time to ready for discharge. 3) Time to the first flatus.
The present disclosure generally relates to systems and methods for treating or preventing aging skin or other indications. For example, some aspects are generally directed to systems and methods for administering a conjugate of a dendrimer and A-acetyl-L-cysteine to a subject, e.g., to the skin of a subject. For example, in one set of embodiments, the conjugate may be applied to aging skin, e.g., to treat or reverse the appearance of aging in the skin. Surprisingly, even though such conjugates can be relatively large (e.g., greater than 3 or 4 nm in diameter) and normally difficult to administer, formulations such as those described herein are effective at facilitating transdermal drug delivery of the conjugates. In addition, in addition to aging skin, other indications may be treated in certain aspects, for example, if the subject has or is at risk of a brain injury or a neurological disorder. Still other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, and the like.
A composite hydrogel comprises an amphiphilic triblock copolymer (ABA) and a loaded micelle bound by noncovalent interactions. The loaded micelle comprises a biologically active substance and an amphiphilic diblock copolymer (CD). The A blocks comprise a steroidal repeat unit (repeat unit 1) having both a backbone carbonate and a side chain bearing a steroid functional group. Each of the A blocks has a degree of polymerization of about 0.5 to about 4.0. The B block comprises a first poly(alkylene oxide) backbone. The C block comprises a second poly(alkylene oxide) backbone. The D block comprises a steroidal repeat unit (repeat unit 2) having both a backbone carbonate group and a side chain comprising a steroid functional group. The composite hydrogel is capable of controlled release of the biologically active substance.